secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-08-27T20:11:23+00:00
Accession:  0001104659-26-102446
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics names Kevin Lundquist CFO, Kenyon departs Sept 1
---------------------------------------------------------------------

- CFO Lawrence Kenyon to step down Sept 1, 2026; stays non-executive through Sept 30, 2026; leaves board by then.
- Kevin Lundquist appointed CFO, Treasurer, principal financial/accounting officer effective Sept 1; previously CFO at CapsoVision (Nasdaq: CV).
- Lundquist receives $450k base salary, 50% target bonus, and option for 500k shares vesting over 4 years.
- Kenyon severance: 12 months base salary + $20k + full 2026 target bonus; 100% option acceleration; 12 months COBRA.
- Board to shrink to eight directors upon Kenyon's board departure; transition not due to any accounting or policy disagreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926102446/0001104659-26-102446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926102446/tm2624167d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-102446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer